Sight Sciences pulled in an equity round worth nearly $31 million for the ophthalmological devices it’s developing, the company said yesterday.

Menlo Park, Calif.-based Sight Sciences logged the first sale of the round August 9, according to a regulatory filing, raising $30.7 million of a hoped-for $31.5 million. Two unnamed investors participated in the round, according to the filing.

In March the company launched a clinical trial of its Omni eye surgery device in sequential, minimally invasive glaucoma procedures. The 130-patient Gemini study is designed to evaluate the use of Omni in consecutive MIGS procedures involving transluminal viscoelastic delivery and trabeculotomy at 12 months.

The single-arm trial’s primary outcomes are change in mean unmedicated diurnal intraocular pressure and change in mean number of IOP-lowering drugs. Secondary outcomes include percent of eyes with a more than 20% reduction in unmedicated diurnal IOP and percent of eyes with unmedicated diurnal IOP between 6mmHg and 18mmHg. The safety endpoints are the rate of ocular adverse events and best corrected visual acuity, according to ClinicalTrials.gov.

The estimate primary completion date is August 2020, with final completion slated for December next year.